+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Intranasal Drug & Vaccine Delivery Market by Drug Type (Analgesics, Antihistamines, Steroids), Formulation Type (Gel Formulations, Liquid Formulations, Powder Formulations), Device Type, Dosage, Application, End-User - Global Forecast 2025-2030- Product Image
Intranasal Drug & Vaccine Delivery Market by Drug Type (Analgesics, Antihistamines, Steroids), Formulation Type (Gel Formulations, Liquid Formulations, Powder Formulations), Device Type, Dosage, Application, End-User - Global Forecast 2025-2030- Product Image
Sale

Intranasal Drug & Vaccine Delivery Market by Drug Type (Analgesics, Antihistamines, Steroids), Formulation Type (Gel Formulations, Liquid Formulations, Powder Formulations), Device Type, Dosage, Application, End-User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 198 Pages
  • March 2025
  • Region: Global
  • 360iResearch™
  • ID: 5533387
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Intranasal Drug & Vaccine Delivery Market grew from USD 46.98 billion in 2023 to USD 49.59 billion in 2024. It is expected to continue growing at a CAGR of 5.88%, reaching USD 70.12 billion by 2030.

This report sets the stage for a deep dive into the dynamic world of intranasal drug and vaccine delivery. The evolution of non-invasive administration has been fueled by advances in biomedical research and innovative engineering solutions. The interest in intranasal approaches is largely driven by the potential to achieve rapid systemic effects and bypass the complications often associated with traditional drug delivery routes. Recent developments have started to unlock possibilities that could transform the therapeutic landscape, offering enhanced bioavailability and improved patient compliance.

In today’s fast-paced healthcare environment, the demand for more efficient, user-friendly, and rapid-acting delivery systems continues to grow. As research and technology converge, stakeholders are presented with new opportunities to leverage intranasal delivery for conditions ranging from routine allergy treatments to complex neurological interventions. The focus is not merely on the method of delivery, but also on the optimization of formulations and devices, ensuring that therapies reach their intended targets with maximum efficacy and minimal side effects.

By examining the trends, innovative breakthroughs, and the competitive dynamics that shape this market, this report provides a strategic outline that informs industry professionals about current challenges and future opportunities. The following sections outline the transformative shifts in the landscape, key segmentation insights, regional trends, major company contributions, and actionable recommendations for industry leaders.

Transformative Shifts in the Intranasal Delivery Landscape

The intranasal drug and vaccine delivery sector has experienced significant transformations over recent years. Rapid advancements in formulation sciences and device engineering have redefined how drugs are administered, leading to efficient and patient-friendly solutions. Technology has played a pivotal role, enabling the development of novel delivery devices that ensure better dosage control, targeted delivery, and improved user experiences. With innovations in nanoparticle encapsulation and absorption enhancers, therapies can now achieve a faster onset of action, while reducing systemic exposure and potential side effects.

Regulatory frameworks have also evolved, becoming more adaptive to emerging technologies and scientific discovery. This adaptability has encouraged a more dynamic market environment where breakthrough products are introduced steadily. The shift in clinical practices from invasive or painful methods to more acceptable intranasal routes has been a game changer, bolstering adoption rates in hospital and homecare settings alike. Furthermore, strategic partnerships and increased investment in research and development have accelerated innovation. Stakeholders across the spectrum, from academic researchers to pharmaceutical giants, are leveraging these advancements to develop next-generation intranasal therapies that meet stringent quality and efficacy standards.

As evidence mounts in clinical trials and real-world applications, it is clear that intranasal delivery is not a mere alternative but a transformative approach that is reshaping the competitive landscape and sparking opportunities to address unmet medical needs. The changing dynamics of market entry barriers and heightened patient awareness are further propelling this transformative shift, making intranasal delivery a cornerstone of future therapeutic strategies.

Comprehensive Insights into Market Segmentation

A detailed examination reveals a multifaceted segmentation strategy that provides a clear view of the market’s diverse offerings. The market is analyzed based on drug type, which encompasses categories such as analgesics, antihistamines, steroids, and vaccines. Particularly, analgesics are further delineated into non-opioids and opioids, providing granularity that supports targeted application and therapy customization. Similarly, vaccines are segmented into inactivated forms, live attenuated variants, and the rapidly emerging mRNA-based vaccines, each reflecting unique development pathways and storage considerations.

Beyond the drug types, the formulation is of critical importance. Products are scrutinized based on whether they are delivered in gel, liquid, or powder formulations. These different forms reflect varied strategies for ensuring stability, ease of administration, and absorption efficiency. The delivery devices further stratify the market, with options including atomizers, nasal droppers, and nasal sprays. This device classification is essential as it directly influences the effectiveness and precision of the administered dose. Dosage approaches are also categorized into multi-dose and unit-dose regimens, accommodating both long-term treatment plans and single, acute interventions.

The market segmentation extends into applications, which range from allergy treatment to hormone replacement, and from managing neurological conditions to addressing pain management and psychiatric disorders. Finally, the end-user dimension spans a wide spectrum from homecare settings to hospitals, clinics, as well as research and academic institutions. This layered segmentation not only supports a robust market analysis but also creates a palette of opportunities for customizing products and services to meet diverse therapeutic needs and operational environments.

Based on Drug Type, market is studied across Analgesics, Antihistamines, Steroids, and Vaccines. The Analgesics is further studied across Non-opioids and Opioids. The Vaccines is further studied across Inactivated Vaccines, Live Attenuated Vaccines, and mRNA-based Vaccine.

Based on Formulation Type, market is studied across Gel Formulations, Liquid Formulations, and Powder Formulations.

Based on Device Type, market is studied across Atomizer, Nasal Dropper, and Nasal Spray.

Based on Dosage, market is studied across Multi-dose and Unit-dose.

Based on Application, market is studied across Allergy Treatment, Hormone Replacement, Neurological Conditions, Pain Management, Psychiatric Disorders, and Therapeutic Drug Delivery.

Based on End-User, market is studied across Homecare, Hospitals & Clinics, and Research & Academic Institution.

Key Regional Market Insights Across Global Territories

A regional perspective reveals significant variations in adoption and innovation across global markets. In the Americas, there is a robust demand fueled by high healthcare expenditure and an accelerating push toward non-invasive alternatives. Advanced infrastructure and a culture of early technology adoption underpin the growth in this region.

Europe, the Middle East, and Africa illustrate a blend of mature markets and emerging economies where both regulatory efficiency and increasing investments in healthcare innovation are paving the way for the adoption of intranasal therapies. Trends analyzing patient-centric care models and precision medicine have become increasingly pertinent in these regions.

Asia-Pacific is rapidly evolving with a strong emphasis on research and an expanding pharmaceutical sector. Shifts in demographic trends coupled with rising disposable incomes have spurred the demand for innovative drug delivery methods. Each of these regions presents unique opportunities and challenges, creating a diverse landscape that underscores local priorities and global trends.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

In-depth Analysis of Leading Market Players

The competitive environment is characterized by a mix of established giants and agile innovators who continuously redefine the boundaries of intranasal drug and vaccine delivery. Industry leaders such as Altimmune, Inc. and AptarGroup, Inc. have demonstrated commitment to pushing technological frontiers, while global pharmaceutical powerhouses like AstraZeneca PLC, Bayer AG, and Becton, Dickinson, and Company are integrating advanced delivery systems into broader portfolios. These efforts are complemented by dynamic contributions from Bharat Biotech Ltd. and Boehringer Ingelheim International GmbH, which consistently bring innovative solutions that meet the growing demands of both developed and emerging markets.

Key players including Catalent, Inc and DCA Design International Limited are combining expertise in formulation science with cutting-edge device engineering to offer comprehensive solutions. Moreover, companies such as Emergent BioSolutions Inc. and GlaxoSmithKline PLC are investing heavily in clinical studies to validate the efficacy of intranasal administrations, enhancing their market credibility. The influence of specialists like Hovione Limited and Impel Pharmaceuticals LLC. is evident in the market’s progression, while the presence of Indivior PLC, and Intersect ENT by Medtronic plc reinforces the significance of precise, targeted drug delivery.

Other major contributors such as Intertek Group PLC, Johnson & Johnson Services, Inc., and Kindeva Drug Delivery L.P. support an ecosystem that merges regulatory expertise with innovation. Furthermore, market players including Merck & Co., Inc., Neurelis, Inc., and Novartis AG are at the forefront of integrating digital solutions that enhance patient compliance and device performance. The extensive list is further enriched by OptiNose, Inc., Pfizer Inc., Recipharm AB., Sanofi S.A., Teleflex Incorporated, and Teva Pharmaceutical Industries Ltd., who collectively underscore the market’s rapid evolution and the intense competitive landscape. Their strategic initiatives and continuous pipeline developments make them key drivers in shaping future trends and sustaining competitive advantage.

The report delves into recent significant developments in the Intranasal Drug & Vaccine Delivery Market, highlighting leading vendors and their innovative profiles. These include Altimmune, Inc., AptarGroup, Inc., AstraZeneca PLC, Bausch Health Companies Inc., Bayer AG, Becton, Dickinson, and Company, Bharat Biotech Ltd., Boehringer Ingelheim International GmbH., Catalent, Inc, DCA Design International Limited, Emergent BioSolutions Inc., GlaxoSmithKline PLC, Hovione Limited, Impel Pharmaceuticals LLC., Indivior PLC, Intersect ENT by Medtronic plc, Intertek Group PLC, Johnson & Johnson Services, Inc., Kindeva Drug Delivery L.P., Merck & Co., Inc., Neurelis, Inc., Novartis AG, OptiNose, Inc., Pfizer Inc., Recipharm AB., Sanofi S.A., Teleflex Incorporated, and Teva Pharmaceutical Industries Ltd..

Actionable Recommendations for Industry Leaders

Industry leaders are encouraged to invest in advanced research and development to consolidate market positioning. Embracing emerging technologies that enhance the bioavailability of intranasally administered formulations is crucial. Companies should focus on integrating state-of-the-art device engineering with robust clinical data, ensuring that regulatory standards are met and exceeded.

It is also advisable to foster cross-industry collaborations that blend expertise in pharmaceutical sciences, engineering, and digital health. Leveraging these partnerships can accelerate the introduction of innovative products while addressing the diverse needs of the patient population. Leaders should continuously monitor evolving regional demands and regulatory environments, thereby adjusting their strategic efforts in a timely manner.

In order to capture new revenue streams, companies should consider targeted investments in market segments that show promising growth potential, such as mRNA-based vaccines and novel powder formulations. Developing personalized therapy options that cater to specific demographic segments could serve as a differentiator in a competitive market. Ultimately, embracing a holistic approach that incorporates cutting-edge research, flexible manufacturing practices, and dynamic marketing strategies will be key to future success.

In summary, the intranasal drug and vaccine delivery market is witnessing rapid innovation driven by technological advancements, detailed segmentation, and global market dynamism. The evolving therapeutic landscape holds significant potential, with industry trends highlighting the importance of integration between scientific discovery and advanced device engineering. Strategic partnerships and investment in R&D further underpin the competitive edge of market leaders, ensuring a sustained trajectory of growth and innovation.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising disease prevalence and syringe infection concerns propel growth in intranasal delivery systems
5.1.1.2. Increasing popularity of self-administration of medications and non-invasive drug delivery routes
5.1.1.3. Growing research and development activities focusing on innovations in intranasal vaccines
5.1.2. Restraints
5.1.2.1. Availability of alternative drug delivery methods and potential risk of product recalls
5.1.3. Opportunities
5.1.3.1. Advancements related to intranasal drug delivery systems
5.1.3.2. Substantial investments for R&D intranasal drug and vaccines delivery innovations
5.1.4. Challenges
5.1.4.1. Potential adverse reactions and side effects associated with intranasal drug administration
5.2. Market Segmentation Analysis
5.2.1. Drug Type: Growing usage of non-opioid analgesics for chronic pain and long-term use owing to the lower risk of addiction and side effects
5.2.2. Formulation Type: Innovative solutions and emerging applications in intranasal drug & vaccine delivery
5.2.3. Device Type: Rising demand for atomizers owing to precision and efficacy in emergency treatments
5.2.4. Dosage: Growing preference for multi-dose formats in large-scale immunization programs and chronic treatment protocols owing to cost-effectiveness and material efficiency
5.2.5. Application: Rising preference for intranasal drug & vaccine delivery in allergy treatment to administer corticosteroids and antihistamines
5.2.6. End-User: Expanding utilization of intranasal drug & vaccine delivery in homecare setups owing to better convenience and privacy
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Intranasal Drug & Vaccine Delivery Market, by Drug Type
6.1. Introduction
6.2. Analgesics
6.2.1. Non-opioids
6.2.2. Opioids
6.3. Antihistamines
6.4. Steroids
6.5. Vaccines
6.5.1. Inactivated Vaccines
6.5.2. Live Attenuated Vaccines
6.5.3. mRNA-based Vaccine
7. Intranasal Drug & Vaccine Delivery Market, by Formulation Type
7.1. Introduction
7.2. Gel Formulations
7.3. Liquid Formulations
7.4. Powder Formulations
8. Intranasal Drug & Vaccine Delivery Market, by Device Type
8.1. Introduction
8.2. Atomizer
8.3. Nasal Dropper
8.4. Nasal Spray
9. Intranasal Drug & Vaccine Delivery Market, by Dosage
9.1. Introduction
9.2. Multi-dose
9.3. Unit-dose
10. Intranasal Drug & Vaccine Delivery Market, by Application
10.1. Introduction
10.2. Allergy Treatment
10.3. Hormone Replacement
10.4. Neurological Conditions
10.5. Pain Management
10.6. Psychiatric Disorders
10.7. Therapeutic Drug Delivery
11. Intranasal Drug & Vaccine Delivery Market, by End-User
11.1. Introduction
11.2. Homecare
11.3. Hospitals & Clinics
11.4. Research & Academic Institution
12. Americas Intranasal Drug & Vaccine Delivery Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States
13. Asia-Pacific Intranasal Drug & Vaccine Delivery Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam
14. Europe, Middle East & Africa Intranasal Drug & Vaccine Delivery Market
14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom
15. Competitive Landscape
15.1. Market Share Analysis, 2023
15.2. FPNV Positioning Matrix, 2023
15.3. Competitive Scenario Analysis
15.3.1. Orexo and Abera collaborate to advance intranasal powder vaccine development
15.3.2. AuraVax Therapeutics secures a research contract from BARDA to investigate NanoSTING platform
15.3.3. Aptar Pharma's strategic acquisition of SipNose enhances innovation in intranasal drug delivery systems
15.3.4. FDA approval for at-home FluMist nasal spray offers needle-free solution to boost flu vaccination rates
15.3.5. Rokote Laboratories partners with 3PBIOVIAN to advance intranasal COVID-19 vaccine manufacturing for clinical trials
15.3.6. CastleVax secures USD 34 million funding to propel innovative intranasal COVID-19 vaccine into advanced trials
15.3.7. BARDA invests USD 500 million in next-generation intranasal and oral COVID-19 vaccines
15.3.8. Merck Animal Health transforms intranasal vaccination with innovative CleanVax nozzles and shields for enhanced hygiene and comfort
15.3.9. Strategic collaboration to innovate nasal drug delivery with soft mist technology
15.3.10. Kindeva expands intranasal drug-delivery capabilities with Summit Biosciences acquisition
15.3.11. Oragenics acquisitions advance intranasal drug delivery for neurological treatments and market expansion
15.4. Strategy Analysis & Recommendation
15.4.1. AstraZeneca PLC
15.4.2. Pfizer Inc.
15.4.3. Indivior PLC
15.4.4. AptarGroup, Inc.
List of Figures
FIGURE 1. INTRANASAL DRUG & VACCINE DELIVERY MARKET MULTI-CURRENCY
FIGURE 2. INTRANASAL DRUG & VACCINE DELIVERY MARKET MULTI-LANGUAGE
FIGURE 3. INTRANASAL DRUG & VACCINE DELIVERY MARKET RESEARCH PROCESS
FIGURE 4. INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2023 VS 2030
FIGURE 5. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 6. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2023 VS 2030 (%)
FIGURE 11. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2023 VS 2030 (%)
FIGURE 13. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2023 VS 2030 (%)
FIGURE 15. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 17. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 19. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 23. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 25. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 27. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 28. INTRANASAL DRUG & VACCINE DELIVERY MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 29. INTRANASAL DRUG & VACCINE DELIVERY MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. INTRANASAL DRUG & VACCINE DELIVERY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. INTRANASAL DRUG & VACCINE DELIVERY MARKET DYNAMICS
TABLE 7. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NON-OPIOIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY STEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY MRNA-BASED VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY GEL FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY LIQUID FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY POWDER FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ATOMIZER, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NASAL DROPPER, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NASAL SPRAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY MULTI-DOSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY UNIT-DOSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ALLERGY TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HORMONE REPLACEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NEUROLOGICAL CONDITIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PSYCHIATRIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY THERAPEUTIC DRUG DELIVERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 50. ARGENTINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 51. ARGENTINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 52. ARGENTINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 53. ARGENTINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 54. ARGENTINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 55. ARGENTINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 56. ARGENTINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 57. ARGENTINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 60. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 61. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 66. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 67. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 68. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 69. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 70. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 71. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 72. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 73. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 74. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 75. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 76. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 77. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 78. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 79. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 80. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 81. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 91. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 92. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 93. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 94. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 95. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 96. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 97. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 98. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 99. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 100. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 101. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 102. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 103. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 104. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 105. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 106. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 107. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 108. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 109. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 110. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 111. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 112. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 113. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 114. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 115. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 116. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 117. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 118. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 119. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 120. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 121. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 122. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 123. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 124. INDONESIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 125. INDONESIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 126. INDONESIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 127. INDONESIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 128. INDONESIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 129. INDONESIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 130. INDONESIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 131. INDONESIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 132. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 133. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 134. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 135. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 136. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 137. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 138. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 139. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 140. MALAYSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 141. MALAYSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 142. MALAYSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 143. MALAYSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 144. MALAYSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 145. MALAYSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 146. MALAYSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 147. MALAYSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 148. PHILIPPINES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 149. PHILIPPINES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 150. PHILIPPINES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 151. PHILIPPINES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 152. PHILIPPINES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 153. PHILIPPINES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 154. PHILIPPINES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 155. PHILIPPINES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 156. SINGAPORE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 157. SINGAPORE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 158. SINGAPORE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 159. SINGAPORE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 160. SINGAPORE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 161. SINGAPORE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 162. SINGAPORE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 163. SINGAPORE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 164. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 165. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 166. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 167. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 168. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 169. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 170. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 171. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 172. TAIWAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 173. TAIWAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 174. TAIWAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 175. TAIWAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 176. TAIWAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 177. TAIWAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 178. TAIWAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 179. TAIWAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 180. THAILAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 181. THAILAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 182. THAILAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 183. THAILAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 184. THAILAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 185. THAILAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 186. THAILAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 187. THAILAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 188. VIETNAM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 189. VIETNAM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 190. VIETNAM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 191. VIETNAM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 192. VIETNAM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 193. VIETNAM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 194. VIETNAM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 195. VIETNAM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 205. DENMARK INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 206. DENMARK INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 207. DENMARK INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 208. DENMARK INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 209. DENMARK INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 210. DENMARK INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 211. DENMARK INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 212. DENMARK INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 213. EGYPT INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 214. EGYPT INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 215. EGYPT INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 216. EGYPT INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 217. EGYPT INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 218. EGYPT INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 219. EGYPT INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 220. EGYPT INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 221. FINLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 222. FINLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 223. FINLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 224. FINLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 225. FINLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 226. FINLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 227. FINLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 228. FINLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 229. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 230. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 231. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 232. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 233. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 234. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 235. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 236. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 237. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 238. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 239. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 240. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 241. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 242. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 243. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 244. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 245. ISRAEL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 246. ISRAEL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 247. ISRAEL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 248. ISRAEL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 249. ISRAEL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 250. ISRAEL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 251. ISRAEL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 252. ISRAEL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 253. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 254. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 255. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 256. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 257. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 258. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 259. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 260. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 261. NETHERLANDS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 262. NETHERLANDS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 263. NETHERLANDS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 264. NETHERLANDS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 265. NETHERLANDS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 266. NETHERLANDS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 267. NETHERLANDS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 268. NETHERLANDS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 269. NIGERIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 270. NIGERIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 271. NIGERIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 272. NIGERIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 273. NIGERIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 274. NIGERIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 275. NIGERIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 276. NIGERIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 277. NORWAY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 278. NORWAY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 279. NORWAY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 280. NORWAY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 281. NORWAY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 282. NORWAY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 283. NORWAY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 284. NORWAY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 285. POLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 286. POLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 287. POLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 288. POLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 289. POLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 290. POLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 291. POLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 292. POLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 293. QATAR INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 294. QATAR INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 295. QATAR INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 296. QATAR INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 297. QATAR INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 298. QATAR INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 299. QATAR INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 300. QATAR INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 301. RUSSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 302. RUSSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 303. RUSSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 304. RUSSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 305. RUSSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 306. RUSSIA INTRANASAL D

Companies Mentioned

  • Altimmune, Inc.
  • AptarGroup, Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Bayer AG
  • Becton, Dickinson, and Company
  • Bharat Biotech Ltd.
  • Boehringer Ingelheim International GmbH.
  • Catalent, Inc
  • DCA Design International Limited
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline PLC
  • Hovione Limited
  • Impel Pharmaceuticals LLC.
  • Indivior PLC
  • Intersect ENT by Medtronic plc
  • Intertek Group PLC
  • Johnson & Johnson Services, Inc.
  • Kindeva Drug Delivery L.P.
  • Merck & Co., Inc.
  • Neurelis, Inc.
  • Novartis AG
  • OptiNose, Inc.
  • Pfizer Inc.
  • Recipharm AB.
  • Sanofi S.A.
  • Teleflex Incorporated
  • Teva Pharmaceutical Industries Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages198
PublishedMarch 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 49.59 Billion
Forecasted Market Value ( USD ) by 2030 $ 70.12 Billion
Compound Annual Growth Rate5.8%
Regions CoveredGlobal
No. of Companies Mentioned28

Related Topics

Related Reports

Intranasal Drug and Vaccine Delivery Market Size, Share & Trends Analysis Report by Product, Dosage, Application, Distribution Channel, Region, and Segment Forecasts, 2025-2030 - Product Image

Intranasal Drug and Vaccine Delivery Market Size, Share & Trends Analysis Report by Product, Dosage, Application, Distribution Channel, Region, and Segment Forecasts, 2025-2030

  • Report
  • 100 Pages
  • Global
From
Vaccine Delivery Devices - Global Strategic Business Report - Product Image

Vaccine Delivery Devices - Global Strategic Business Report

  • Report
  • 93 Pages
  • Global
From
Vaccine Delivery Devices Market by Nature, Product Type - Global Forecast 2025-2030 - Product Image

Vaccine Delivery Devices Market by Nature, Product Type - Global Forecast 2025-2030

  • Report
  • 181 Pages
  • Global
From
Vaccine Delivery Devices Market Size, Share & Trends Analysis Report By Device (Syringes, Jet Injectors), By Route Of Administration (Intradermal Vaccination, Intramuscular Vaccination, Subcutaneous Vaccination), By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Vaccine Delivery Devices Market Size, Share & Trends Analysis Report By Device (Syringes, Jet Injectors), By Route Of Administration (Intradermal Vaccination, Intramuscular Vaccination, Subcutaneous Vaccination), By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 170 Pages
  • Global
From
Vaccine Delivery Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Vaccine Delivery Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 182 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.